MedDataX Logo

Balance Confidence and Kinesiophobia in Parkinson's Disease

NCT ID: NCT06751797

Last Updated: 2024-12-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

62 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-10

Study Completion Date

2025-01-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

31 patients aged 50-80 years diagnosed with idiopathic Parkinson's disease (Modified Hoehn-Yahr stages 1-3) and 31 healthy volunteers. At the start of the study, sociodemographic data for all participants will be recorded. To assess the mental and functional status of Parkinson's disease patients, the Mini-Mental State Examination (MMSE) and the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) will be used. Balance confidence levels will be assessed using the Activities-specific Balance Confidence Scale-6 (ABC-6), overall balance using the Berg Balance Scale (BBS), fear of falling using the Falls Efficacy Scale (FES), and kinesiophobia levels using the Tampa Scale of Kinesiophobia (TSK).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Parkinson disease group

Patient with parkinson disease

No intervention

Intervention Type OTHER

No intervention

Control group

Healthy controls

No intervention

Intervention Type OTHER

No intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

No intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Idiopathic Parkinson's Disease by a neurology specialist.
* Modified Hoehn-Yahr Staging Scale classification between stages 1-3.
* Mini-Mental State Examination (MMSE) score of 24 or higher.
* Age between 50-80 years.
* Volunteered to participate in the study.

Exclusion Criteria

* Use of medications, apart from routine Parkinson's disease treatments, that could affect balance or muscle strength.
* Presence of neurological or musculoskeletal conditions other than Parkinson's disease.
* Refusal to participate in the study.
* Presence of psychiatric disorders.
* Presence of cognitive impairments.
Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beylikduzu State Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Busra Sirin

Principle Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beylikdüzü State Hospital

Istanbul, Beylikdüzü, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Büşra Şirin Ahısha, MD

Role: CONTACT

Phone: 02124443322

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Büşra Şirin

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BeylikduzuStateH13

Identifier Type: -

Identifier Source: org_study_id